Reirradiation and XXXX in rectal carcinoma: a retrospective study on palliative effect.

@entity1 @entity137 @entity5 @entity158 @entity14 @entity221
BACKGROUND: The objective of this study was to evaluate the palliative effect of reirradiation and @entity221 in @entity1 with unresectable, recurrent @entity14 . METHODS: The medical records of 54 @entity1 with unresectable, recurrent @entity14 that caused @entity158 and who were treated with reirradiation and @entity221 , were evaluated retrospectively. Previous radiotherapy was given up to a total dose ranging from 25-70 grays (Gy). The median interval between prior radiotherapy and reirradiation was 22 months (range, 4-97 months). The total reirradiation dose varied from 24 Gy to 32 Gy given in fractions of 4 Gy twice weekly. Three or four @entity221 treatments were given once weekly. @entity137 was registered. The influence of World Health Organization (WHO) performance status, maximum @entity5 dimension, and time between first radiotherapy and reirradiation on therapeutic outcome was evaluated. The results of this study were compared with published results on @entity1 who received radiotherapy with or without @entity221 . RESULTS: Forty-seven @entity1 (87%) completed the planned treatment schedule. The maximum @entity137 was Grade 2. All @entity1 were evaluated for palliative effect. The median follow-up was 10 months. A good or complete palliative effect was achieved in 72% of @entity1 for a median duration of 6 months. @entity1 who had a better WHO performance status, smaller @entity5 , and a longer interval between first radiotherapy and reirradiation had slightly better outcomes, although none of those parameters reached statistical significance. CONCLUSIONS: The described combined treatment was feasible and well tolerated. Comparison of results from radiotherapy plus @entity221 with results after radiotherapy alone suggested that additional @entity221 prolonged the duration of palliation. Firm proof of the contribution of @entity221 will require performing a Phase III study.
